Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery
Publication Date : //
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.
Phase 3 studies of bevacizumab in patients with advanced pancreatic cancer (APCA) demonstrated no improvement in outcome. To the authors' knowledge, no validated predictive biomarkers for bevacizumab exist, although emerging data suggest that subsets of patients with APCA may benefit from treatment with bevacizumab. The authors evaluated baseline serum albumin (b-alb) as a predictive biomarker in a pooled analysis from 7 prospective clinical trials of gemcitabine-based therapy with or without bevacizumab.
Authors : Pant Shubham , Martin Ludmila K , Geyer Susan , Wei Lai , Van Loon Katherine , Sommovilla Nili , Sommovilla Nilli , Zalupski Mark , Iyer Renuka , Fogelman David , Ko Andrew H , Bekaii-Saab Tanios ,
Related products :
52062 Aachen Deutschland
Support Karolina Elandt
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
firstname.lastname@example.org | Gentaur
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Finland Helsset +358942419041
Magyarország Budapest +3619980547
US New York+17185132983
WP2256: Integrated Pancreatic Cancer Pathway
WP2367: Private Pancreatic Cancer
WP2377: Integrated Pancreatic Cancer Pathway
WP1589: Folate-Alcohol and Cancer Pathway
WP1781: Advanced glycosylation endproduct receptor signaling
WP1968: genetic alternations of lung cancer
WP1971: Integrated Cancer pathway
WP1984: Integrated Breast Cancer Pathway
WP2107: pathways in human cancer
WP2263: Prostate Cancer
WP2291: Deregulation of Rab and Rab Effector Genes in Bladder Cancer
WP2335: sGC Cancer
WP2361: Gastric cancer network 1
WP2363: Gastric cancer network 2
WP2411: Cancer prevention Q
WP2429: Cancer prevention Q
Related Genes :
 Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in Wild-Type Metastatic Colorectal Cancer.
 The mode of progressive disease affects the prognosis of patients with metastatic breast cancer.
 The Methylation Status of the Epigenome: Its Emerging Role in the Regulation of Tumor Angiogenesis and Tumor Growth, and Potential for Drug Targeting.
 Improvement of Mycobacterium abscessus Pulmonary Disease after Nivolumab Administration in a Patient with Advanced Non-Small Cell Lung Cancer: A Case Report.
 An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
 Favorable response to pemetrexed, cisplatin and bevacizumab in invasive mucinous adenocarcinoma: A case report and literature review.
 Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports.
 Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type metastatic colorectal cancer: a meta-analysis.
 Impact of time to start systemic therapy on the outcomes of patients with metastatic colorectal cancer treated with first line FOLFOX chemotherapy; a patient-level pooled analysis of two clinical trials.
 Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores.
Enter catalog number :